Brenus secures €11M to advance colorectal cancer vaccine development in a Series A extension, increasing total funding to €33.2M. The investment includes participation from existing and new investors.
Amount Raised
€11 Million
Round Type
Series A
LyonBiotechnologyHealth CareTherapeuticsInvestors
Description
Brenus, a Lyon-based biotech, has added €11M in extension funding to its Series A round, bringing the total for this round to €33.2M. This round aims to propel the development of STC-1010, its lead therapeutic cancer vaccine. Notable participants in this funding include existing investors and new entrants like Sambrinvest and Korea Omega Investment Corp. The company has raised a total of €38 million since its inception.
Quick answer
Brenus raised €11 Million in a Series A round, dated July 21, 2026. Investors: Korea Omega Investment Corp, Sambrinvest, Bio Jag, Orsa, Noshaq, Crédit Agricole, UI Investissement and Angelor. Brenus is based in Lyon, Auvergne Rhône Alpes, France.
- How much did Brenus raise?
- Brenus raised €11 Million in a Series A round on July 21, 2026.
- Who invested in Brenus?
- Korea Omega Investment Corp, Sambrinvest, Bio Jag, Orsa, Noshaq, Crédit Agricole, UI Investissement and Angelor are named as investors in this round.
- What does Brenus do?
- Brenus is a Lyon-based biotech company focused on developing immunotherapy treatments for microsatellite-stable metastatic colorectal cancer (MSS mCRC).
- Where is Brenus based and how big is it?
- Brenus is based in Lyon, Auvergne Rhône Alpes, France.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Brenus that raised within 45 days of this round, from Fundz verified event records.
- Dimerix Limited raised $25M (Debt Financing) on September 4, 2026.
- ZoeNCure Therapeutics Pvt. Ltd raised $2.4M (Seed) on September 3, 2026.
- NovaGo Therapeutics AG raised $30M (Series B) on September 2, 2026.
- Typewriter Therapeutics raised $56M (Series A) on September 2, 2026.
- NovaGo Therapeutics raised $30M (Series B) on September 2, 2026.
- CytoDyn raised $17M on September 1, 2026.
Who to call at Brenus, and when
A new round usually means Brenus is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Brenus raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Brenus, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Brenus. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Brenus raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansBrenus raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.